TNFSF13B and B-cell chronic lymphocytic leukemia: Next we exposed primary CLL cells to idelalisib, ibrutinib or venetoclax in the presence or absence of BAFF with or without belimumab or control antibody and determined CLL cell viability by CTG assays.